Last reviewed · How we verify
SR-fampridine
SR-fampridine is a Potassium channel blocker Small molecule drug developed by University of Southern Denmark. It is currently FDA-approved for Multiple sclerosis (to improve walking ability), Spinal cord injury. Also known as: Fampyra.
SR-fampridine is a sustained-release formulation of fampridine that blocks potassium channels in nerve fibers, prolonging action potentials and enhancing nerve conduction.
SR-fampridine is a medication used to treat conditions such as Multiple Sclerosis and Working Memory, as indicated by studies on ClinicalTrials.gov. The exact mechanism of SR-fampridine is unknown, according to ChEMBL.
At a glance
| Generic name | SR-fampridine |
|---|---|
| Also known as | Fampyra |
| Sponsor | University of Southern Denmark |
| Drug class | Potassium channel blocker |
| Target | Voltage-gated potassium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Fampridine is a broad-spectrum potassium channel blocker that increases the duration of the action potential in demyelinated nerve fibers, thereby improving conduction across damaged segments. The sustained-release formulation allows for twice-daily dosing with improved tolerability compared to immediate-release formulations. This mechanism is particularly beneficial in demyelinating diseases where nerve conduction is impaired.
Approved indications
- Multiple sclerosis (to improve walking ability)
- Spinal cord injury
Common side effects
- Seizures
- Urinary tract infection
- Insomnia
- Dizziness
- Headache
Key clinical trials
- Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression (PHASE2)
- Influence of Fampridine on Working Memory in Healthy Subjects (PHASE2)
- Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive Impairment (NA)
- Influence of Fampridine on Working Memory in Healthy Young Subjects (PHASE2)
- Fampridine-SR and Optic Neuritis Recovery (EARLY_PHASE1)
- Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury (PHASE3)
- Study of Oral Fampridine-SR in Multiple Sclerosis (PHASE3)
- FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SR-fampridine CI brief — competitive landscape report
- SR-fampridine updates RSS · CI watch RSS
- University of Southern Denmark portfolio CI
Frequently asked questions about SR-fampridine
What is SR-fampridine?
How does SR-fampridine work?
What is SR-fampridine used for?
Who makes SR-fampridine?
Is SR-fampridine also known as anything else?
What drug class is SR-fampridine in?
What development phase is SR-fampridine in?
What are the side effects of SR-fampridine?
What does SR-fampridine target?
Related
- Drug class: All Potassium channel blocker drugs
- Target: All drugs targeting Voltage-gated potassium channels
- Manufacturer: University of Southern Denmark — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Multiple sclerosis (to improve walking ability)
- Indication: Drugs for Spinal cord injury
- Also known as: Fampyra
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing